[go: up one dir, main page]

WO2022012610A1 - Compositions et procédés permettant de cibler l'anticorps anti-tnf-alpha - Google Patents

Compositions et procédés permettant de cibler l'anticorps anti-tnf-alpha Download PDF

Info

Publication number
WO2022012610A1
WO2022012610A1 PCT/CN2021/106404 CN2021106404W WO2022012610A1 WO 2022012610 A1 WO2022012610 A1 WO 2022012610A1 CN 2021106404 W CN2021106404 W CN 2021106404W WO 2022012610 A1 WO2022012610 A1 WO 2022012610A1
Authority
WO
WIPO (PCT)
Prior art keywords
sequence
polynucleotide
seq
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2021/106404
Other languages
English (en)
Inventor
Lingjie Kong
Jean Wang
Tianwei GUO
Shicheng ZHU
Ying Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Porton Biologics Ltd
Original Assignee
Porton Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Porton Biologics Ltd filed Critical Porton Biologics Ltd
Priority to US18/005,669 priority Critical patent/US20230287097A1/en
Priority to EP21843504.8A priority patent/EP4182459A4/fr
Priority to CN202180002562.8A priority patent/CN113646433B/zh
Publication of WO2022012610A1 publication Critical patent/WO2022012610A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/17—Hinge-spacer domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/21—Transmembrane domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/22—Intracellular domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • the present disclosure generally relates to therapeutics including treatment with immunosuppressive medication.
  • the present disclosure relates to compositions and methods for boosting response to the treatment with a therapeutic anti-TNF alpha monoclonal antibody.
  • ADAs anti-drug antibodies
  • ADAs anti-drug antibodies
  • ADAs can lead to enhanced clearance of the therapeutic antibodies and prevent the drug from binding to the target.
  • Efforts to develop chimeric, humanized and fully human antibodies did not fully abolish the immunogenicity of the therapeutic antibodies and the associated induction of ADAs.
  • TNF-alpha tumor necrosis factor alpha
  • ADAs impaired the clinical response to anti-TNA-alpha antibodies and/or elicited adverse events, leading to medical consequences including increase of dosage or dosing frequency, concomitant use of immune modulating drugs, discontinuation of the treatment or switch to other TNF-alpha antagonist (Atiqi S, et al., Front Immunol. 2020; 11: 312, Homann A et al. J Transl Med (2015) 13: 339) . Therefore, a need exists for eliminating the ADAs to boost clinical response and/or eliminate adverse events associated with the therapeutic anti-TNF-alpha monoclonal antibodies.
  • the present disclosure provides a polynucleotide encoding a chimeric anti-drug antibody receptor (CADAR) .
  • the chimeric anti-drug antibody receptor comprises an extracellular domain comprising an immunogenic fragment of a therapeutic anti-TNF-alpha monoclonal antibody, a transmembrane domain and an intracellular signaling domain, wherein the immunogenic fragment binds to a B cell receptor (BCR) expressed on a B-cell, wherein a cell expressing the CADAR binds the BCR expressed on the B-cell or induces killing of the B-cell expressing the anti-drug antibody.
  • BCR B cell receptor
  • the immunogenic fragment comprises a heavy chain variable region or light chain variable region of the therapeutic anti-TNF-alpha monoclonal antibody, a sequence having at least 90%identify thereof, or a sequence having 1, 2, 3, 4, 5 amino acid residue difference therefrom.
  • the immunogenic fragment comprises a scFV that comprises the heavy chain variable region and the light chain variable region of the therapeutic anti-TNF-alpha monoclonal antibody, a sequence having at least 90%identify thereof, or a sequence having 1, 2, 3, 4, 5 amino acid residue difference therefrom.
  • the therapeutic anti-TNF-alpha monoclonal antibody is selected from adalimumab, infliximab, afelimomab, golimumab, and certolizumab.
  • the immunogenic fragment comprises a heavy chain variable region or light chain variable region as listed in Table 1, a sequence having at least 90%identify thereof, or a sequence having 1, 2, 3, 4, 5 amino acid residue difference therefrom.
  • the immunogenic fragment comprises a scFv that comprises the paired heavy chain variable region and light chain variable region as listed in Table 1, a sequence having at least 90%identify thereof, or a sequence having 1, 2, 3, 4, 5 amino acid residue difference therefrom.
  • the therapeutic anti-TNF-alpha monoclonal antibody is adalimumab and the immunogenic fragment comprises (a) one or more sequences selected from the group of sequences listed in Table 2, or one or more sequences having at least 90%identity thereto, or one or more sequences having 1, 2, 3, 4, or 5 amino acid residue difference therefrom; or (b) a TNF-alpha binding fragment of adalimumab, or a sequence having at least 90%identity thereto, or a sequence having 1, 2, 3, 4, or 5 amino acid residue difference therefrom; or a combination of (a) and (b) .
  • the therapeutic anti-TNF-alpha monoclonal antibody is infliximab and the immunogenic fragment comprises (a) one or more sequences selected from the group of sequences listed in Table 3, or one or more sequences having at least 90%identity thereto, or one or more sequences having 1, 2, 3, 4, or 5 amino acid residue difference from any of the group of sequences listed in Table 3; or (b) a TNF-alpha binding fragment of infliximab, or a sequence having at least 90%identity thereto, or a sequence having 1, 2, 3, 4, or 5 amino acid residue difference therefrom; or a combination of (a) and (b) .
  • the chimeric receptor further comprises a signal peptide of CD8 alpha.
  • the signal domain of CD8 alpha comprises the sequence of SEQ ID NO: 20 or a sequence having at least 90%identity thereto or a sequence having 1, 2, 3, 4, or 5 amino acid residue difference therefrom.
  • the transmembrane domain comprises a transmembrane domain of CD8 alpha.
  • the transmembrane domain of CD8 alpha comprises the sequence of SEQ ID NO: 21, or a sequence having at least 90%identity thereto or a sequence having 1, 2, 3, 4, or 5 amino acid residue difference therefrom.
  • the extracellular domain is linked to the transmembrane domain by a hinge region.
  • the hinge region comprises a hinge region of CD8 alpha.
  • the hinge region of CD8 alpha comprises the sequence of SEQ ID NO: 22, or a sequence having at least 90%identity thereto or a sequence having 1, 2, 3, 4, or 5 amino acid residue difference therefrom.
  • the intracellular domain comprises a costimulatory domain and a signaling domain.
  • the costimulatory domain comprises an intracellular domain of CD137.
  • the intracellular domain of CD137 comprises the sequence of SEQ ID NO: 23, or a sequence having at least 95%identity thereto.
  • the intracellular domain comprises a signaling domain of CD3 zeta.
  • the signaling domain of CD3 zeta comprises the sequence of SEQ ID NO: 24, or a sequence having at least 95%identity thereto.
  • the present disclosure provides a polypeptide encoded by the polynucleotide as describe herein.
  • the present disclosure provides vector comprising the polynucleotide as described herein, wherein the polynucleotide encoding the CADAR is operatively linked to at least one regulatory polynucleotide element for expression of the CADAR.
  • the vector is a plasmid vector, a viral vector, a transposon, a site directed insertion vector, or a suicide expression vector.
  • the vector is a lentiviral vector, a retroviral vector, or an AAV vector.
  • the present disclosure provides an engineered cell comprising the vector as described herein.
  • the engineered cell is a T cell or an NK cell.
  • the present disclosure provides a method of boosting response to the treatment with a therapeutic anti-TNF alpha monoclonal antibody in a subject in need thereof, comprising administering an effective amount of the engineered cell as described herein.
  • the subject has a condition selected from rheumatoid arthritis (RA) , Juvenile idiopathic arthritis (JIA) , psoriatic arthritis (PsA) , ankylosing spondylitis (AS) , adult Crohn’s disease (CD) , pediatric Crohn’s disease, ulcerative colitis (UC) , plaque psoriasis (Ps) , hidradenitis suppurativa (HS) and uveitis (UV) .
  • RA rheumatoid arthritis
  • JIA Juvenile idiopathic arthritis
  • PsA psoriatic arthritis
  • AS ankylosing spondylitis
  • CD adult Crohn’s disease
  • CD adult Crohn’s disease
  • UC ulcerative colitis
  • Ps plaque psoriasis
  • HS hidradenitis suppurativa
  • UV uveitis
  • the subject does not respond to or lose initial response to the treatment with the therapeutic anti-TNF alpha monoclonal antibody.
  • the therapeutic anti-TNF alpha monoclonal antibody induces anti-drug antibodies in the subject.
  • the engineered cell is an autologous cell. In some embodiments, the engineered cell is an allogeneic cell.
  • the method further comprises administering an agent that increases the efficacy of the engineered cells. In some embodiments, the method further comprises administering an agent that ameliorates a side effect associated with the administration of the engineered cells.
  • FIG. 1 illustrates that chimeric anti-drug antibody receptor (CADAR) expressed on engineered T cells target B-cell receptor (BCR) expressed on certain B cells that produce ADA against adalimumab.
  • CADAR chimeric anti-drug antibody receptor
  • BCR B-cell receptor
  • FIG. 2 illustrates a schematic diagram of an exemplary CADAR construct.
  • Antigen refers to a molecule that provokes an immune response. This immune response may be either humoral, or cell-mediated response, or both. The skilled artisan will understand that any macromolecule, including virtually all proteins or peptides, can serve as an antigen. It is readily apparent that the present disclosure includes therapeutic antibodies acting as antigen eliciting immune response.
  • Antibody refers to a polypeptide of the immunoglobulin (Ig) family that binds with an antigen.
  • Ig immunoglobulin
  • a naturally occurring “antibody” of the IgG type is a tetramer comprising at least two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds.
  • Each heavy chain is comprised of a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region.
  • the heavy chain constant region is comprised of three domains, CH1, CH2 and CH3.
  • Each light chain is comprised of a light chain variable region (abbreviated herein as VL) and a light chain constant region.
  • the light chain constant region is comprised of one domain (abbreviated herein as CL) .
  • VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR) , interspersed with regions that are more conserved, termed framework regions (FR) .
  • CDR complementarity determining regions
  • FR framework regions
  • Each VH and VL is composed of three CDRs and four FRs arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
  • the variable regions of the heavy and light chains contain a binding domain that interacts with an antigen.
  • “Monoclonal antibody” refers to an antibody that is made by identical immune cells that are all clones of a unique parent cell.
  • Anti-idiotypic antibody refers to an antibody which binds to the idiotype of another antibody.
  • Immunotype refers to the antigenic determinants of immunoglobulin molecules that are located in the variable region of the antibodies.
  • Anti-drug antibody or “ADA” refers to antibodies elicited in vivo by a therapeutic drug, including a therapeutic antibody. ADAs are directed against immunogenic parts of the therapeutic drug and may affect the efficacy, pharmacokinetics and safety of the treatment with the therapeutic antibody.
  • Autologous cells refer to any cells derived from the same subject into which they are later to be re-introduced.
  • Allogeneic cells refer to any cells derived from a different subject of the same species.
  • B-cell receptor or “BCR” refers to a transmembrane immunoglobulin molecule on the surface of B cell that recognize a specific antigen.
  • CADAR Chimeric anti-drug antibody receptor
  • a CADAR is a fusion polypeptide comprises an extracellular domain that introduces the desired specificity, a transmembrane domain and an intracellular domain that transmits a signal to the immune cells when the immune cells bind to the anti-drug antibody or the specific BCR.
  • Co-stimulatory ligand refers to a molecule on an antigen presenting cell (e.g., an APC, dendritic cell, B cell, and the like) that specifically binds a cognate co-stimulatory molecule on a T cell, thereby providing a signal which, in addition to the primary signal provided by, for instance, binding of a TCR/CD3 complex with an major histocompatibility complex (MHC) molecule loaded with peptide, mediates a T cell response, including, but not limited to, proliferation, activation, differentiation, and the like.
  • MHC major histocompatibility complex
  • Co-stimulatory molecule refers to the cognate binding partner on a T cell that specifically binds with a co-stimulatory ligand, thereby mediating a co-stimulatory response by the T cell, such as, but not limited to, proliferation.
  • Co-stimulatory molecules include, but are not limited to an MHC class I molecule, BTLA and a Toll ligand receptor.
  • Effector cells used in the context of immune cells refers to cells that can be activated to carry out effector functions in response to stimulation. Effector cells may include, without limitation, NK cells, cytotoxic T cells and helper T cells.
  • Effective amount refers to an amount of a cell, composition, formulation or any material as described here effective to achieve a desirable biological result. Such results may include, without limitation, elimination of B cells expressing a specific BCR and the antibodies produced therefrom.
  • Epitope or “immunogenic fragment” or “antigenic determinant” refers to a portion of an antigen recognized by an antibody or an antigen-binding fragment thereof. An epitope can be linear or conformational.
  • Percentage of “identity” or “sequence identity” in the context of polypeptide or polynucleotide is determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.
  • “Operatively linked” refers to a functional relationship between two or more polynucleotide sequences.
  • a polynucleotide encoding a fusion protein such as a polypeptide chain of a CADAR of the disclosure
  • the term means that the two or more polynucleotide sequences are joined such that the amino acid sequences encoded by these segments remain in-frame.
  • transcriptional or translational regulation the term refers to the functional relationship of a regulatory sequence to a coding sequence, for example, a promoter in the correct location and orientation to the coding sequence so as to modulate the transcription.
  • Immunogenicity refers to the ability of a foreign substance, such as an antigen, to provoke an immune response in the body of a subject.
  • the immunogenic response typically includes both cell-mediated and humoral arms of the immune response.
  • an “immunogenic fragment” refers to a region of the antibody that elicit the immune response of the host. Such response can lead to the production of anti-drug antibody (ADA) against the therapeutic antibody compromising the therapeutic effects of the treatment.
  • ADA anti-drug antibody
  • Polynucleotide or “nucleic acid” refers to a chain of nucleotides. As used herein polynucleotides include all polynucleotide sequences which are obtained by any means available in the art, including, without limitation, recombinant means by synthetic means.
  • Polypeptide, ” and “protein” are used interchangeably, and refer to a chain of amino acid residues covalently linked by peptide bonds.
  • the polypeptides include natural peptides, recombinant peptides, synthetic peptides, or a combination thereof.
  • Single-chain Fv antibody or “scFv” refers to an engineered antibody comprises a light chain variable region fused to a heavy chain variable region directly or via a peptide linker sequence.
  • T cell receptor or “TCR” refers to a protein complex on the surface of T cells that is responsible for recognizing fragments of antigen as peptides bound to MHC molecules.
  • TNF-alpha Tumor necrosis factor- ⁇ or “TNF-alpha” is a multifunctional pro-inflammatory cytokine secreted predominantly by monocytes or macrophages that has effects on lipid metabolism, coagulation, insulin resistance, and endothelial function. TNF has been implicated in inflammatory diseases, autoimmune diseases, viral, bacterial and parasitic infections, malignancies, and/or neurodegenerative diseases and is a useful target for specific biological therapy.
  • Vector refers to a vehicle into which a polynucleotide may be operably inserted so as to deliver, replicate or express the polynucleotide.
  • a vector may contain a variety of regulatory elements including, without limitation, origin of replication, promoter, transcription initiation sequences, enhancer, selectable marker genes, and reporter genes.
  • a vector may also include materials to aid in its entry into a host cell, including but not limited to a viral particle, a liposome, or ionic or amphiphilic compounds.
  • Therapeutic monoclonal antibodies targeting TNF-alpha have been widely used in clinics to treat rheumatoid arthritis, inflammatory bowel disease, and other chronic inflammatory associated disorders such as psoriasis, psoriatic arthritis, and ankylosing spondylitis.
  • a well-known side effect associated with the therapeutic anti-TNF-alpha antibodies is the development of anti-drug antibodies (ADAs) , which leads to enhanced clearance of the therapeutic antibodies and prevent the drug from binding to the target, thus interfering the therapy outcome.
  • ADAs anti-drug antibodies
  • the present disclosure in one aspect relates to the chimeric anti-drug antibody receptors (CADARs) that specifically binds to the B-cell receptor (BCR) expressed on certain B cells that produce ADA against the therapeutic anti-TNF-alpha antibodies (FIG. 1) .
  • CADARs chimeric anti-drug antibody receptors
  • BCR B-cell receptor
  • FOG. 1 therapeutic anti-TNF-alpha antibodies
  • the present disclosure provides a CADAR comprising an extracellular domain, a transmembrane domain and an intracellular signaling domain, whereas the extracellular domain comprises an immunogenic fragment of a therapeutic anti-TNF-alpha monoclonal antibody.
  • the present disclosure provides a polynucleotide encoding the CADAR described herein.
  • the extracellular domain of the CADAR described herein comprises an immunogenic fragment of a therapeutic anti-TNF-alpha monoclonal antibody. While the immunogenic fragment is recognized by the ADA against the therapeutic anti-TNF-alpha monoclonal antibody, the immunogenic fragment specifically binds to the BCR of the B-cells that express such ADA.
  • the immunogenic fragment of the present disclosure can be derived from any therapeutic anti-TNF-alpha monoclonal antibodies known in the art, for example, those disclosed in patents US6258562B1, US6284471B1, EP2185201A1, US8241899B2, US8603778B2, US7521206B2, US7012135B2, US7186820B2, US7402662B2 and CN1289671C.
  • the therapeutic anti-TNF-alpha monoclonal antibody from which the immunogenic fragment of the present disclosure is derived is selected from adalimumab, infliximab, afelimomab and golimumab. It should be noted that when reference is made to an anti-TNF-alpha antibody, e.g., adalimumab, the fragments, derivatives and modifications thereof are also included unless the context dictates otherwise.
  • the therapeutic anti-TNF-alpha monoclonal antibody from which the immunogenic fragment of the present disclosure is derived comprises the heavy and light chain variable region sequences set forth in Table 1.
  • the immunogenic fragment of a therapeutic anti-TNF-alpha monoclonal antibody includes an epitope recognized by an ADA against the therapeutic antibody. It has been discovered that the ADAs can be anti-idiotypic antibodies directed against the antigen-binding region of the therapeutic monoclonal antibody and thus prevent binding of the therapeutic antibody to TNF-alpha.
  • the therapeutic anti-TNF-alpha monoclonal antibody is adalimumab
  • the extracellular domain of the CADAR comprises one or more sequences selected from the group of sequences listed in Table 2, or one or more sequences having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%sequence identity thereto, or one or more sequences having 1, 2, 3, 4, or 5 amino acid residue difference therefrom.
  • the therapeutic anti-TNF-alpha monoclonal antibody is infliximab and the extracellular domain of the CADAR comprises one or more sequences selected from the group of sequences listed in Table 3, or one or more sequences having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%sequence identity thereto, or one or more sequences having 1, 2, 3, 4, or 5 amino acid residue difference therefrom.
  • the extracellular domain of the CADAR comprises one or more antigen binding fragment of the therapeutic anti-TNF-alpha monoclonal antibody.
  • Antigen binding fragment refers to a portion of an antibody comprising one or more CDRs, or any other antibody fragment that binds to an antigen but does not comprise an intact native antibody structure. It can be understood that the antigen binding fragment in the context of anti-TNF-alpha monoclonal refers to a portion of the antibody that binds to TNF-alpha.
  • Antigen binding fragments useful for the present disclosure include, without limitation, a scFv or a fragment thereof (e.g., VL, VH, CDRs) .
  • the antigen binding fragment is a scFv derived the anti-TNF antibodies listed in Table 1.
  • the scFv comprises the paired heavy chain variable region and light chain variable region as listed in Table 1.
  • the therapeutic anti-TNF-alpha monoclonal antibody is adalimumab
  • the extracellular domain of the CADAR comprises a combination of (a) one or more sequences selected from the group of sequences listed in Table 2 or a sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%sequence identity thereto, or one or more sequences having 1, 2, 3, 4, or 5 amino acid residue difference therefrom; and (b) an antigen binding fragment of adalimumab, or a sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%sequence identity thereto, or one or more sequences having 1, 2, 3, 4, or 5 amino acid residue difference therefrom.
  • the therapeutic anti-TNF-alpha monoclonal antibody is infliximab
  • the extracellular domain of the CADAR comprises a combination of (a) one or more sequences selected from the group of sequences listed in Table 3 or sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%sequence identity thereto, or one or more sequences having 1, 2, 3, 4, or 5 amino acid residue difference therefrom; and (b) an antigen binding fragment of infliximab, or a sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%sequence identity thereto, or one or more sequences having 1, 2, 3, 4, or 5 amino acid residue difference therefrom.
  • the extracellular domain further comprises a signal peptide.
  • signal peptide refers to peptide, usually having a length of 5-30 amino acid residues, present at the N-terminus of a polypeptide that necessary for the translocation cross the membrane on the secretory pathway and control of the entry of the polypeptide to the secretory pathway.
  • the signal peptide comprises a signal peptide of CD8 alpha: In some embodiments, the signal peptide of CD8 alpha comprises a sequence of SEQ ID NO: 20 or a sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%sequence identity thereto. In some embodiments, the signal peptide comprises a signal peptide of IgG.
  • the transmembrane domain of the CADAR described herein may be derived from any membrane-bound or transmembrane protein including, but are not limited to, BAFFR, BLAME (SLAMF8) , CD2, CD3 epsilon, CD4, CD5, CD8, CD9, CD11a (CD18, ITGAL, LFA-l) , CD11b, CD11c, CD11d, CD16, CD19, CD22, CD27, CD28, CD29, CD33, CD37, CD40, CD45, CD49a, CD49d, CD49f, CD64, CD80, CD84, CD86, CD96 (Tactile) , CD100 (SEMA4D) , CD103, CD134, CD137 (4-1BB) , CD150 (IPO-3, SLAMF1, SLAM) , CD154, CD160 (BY55) , CD162 (SELPLG) , CD226 (DNAM1) , CD229 (Ly9) , CD244 (2B4, SLA
  • the CADAR described herein comprises a transmembrane domain of CD8 alpha, CD28 or ICOS.
  • the transmembrane domain of CD8 alpha has a sequence of SEQ ID NO: 21, or a sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%sequence identity thereto.
  • the transmembrane domain of the CADAR described herein is synthetic, e.g., comprising predominantly hydrophobic residues such as leucine and valine.
  • the transmembrane domain of the CADAR described herein is modified or designed to avoid binding to the transmembrane domains of the same or different surface membrane proteins in order to minimize interactions with other members of the receptor complex.
  • the CADAR described herein further comprises a hinge region, which forms the linkage between the extracellular domain and transmembrane domain of the CADAR.
  • the hinge and/or transmembrane domain provides cell surface presentation of the extracellular domain of the CADAR.
  • the hinge region may be derived from any membrane-bound or transmembrane protein including, but are not limited to, BAFFR, BLAME (SLAMF8) , CD2, CD3 epsilon, CD4, CD5, CD8, CD9, CD11a (CD18, ITGAL, LFA-l) , CD11b, CD11c, CD11d, CD16, CD19, CD22, CD27, CD28, CD29, CD33, CD37, CD40, CD45, CD49a, CD49d, CD49f, CD64, CD80, CD84, CD86, CD96 (Tactile) , CD100 (SEMA4D) , CD103, CD134, CD137 (4-1BB) , CD150 (IPO-3, SLAMF1, SLAM) , CD154, CD160 (BY55) , CD162 (SELPLG) , CD226 (DNAM1) , CD229 (Ly9) , CD244 (2B4, SLAMF4) , CD278 (ICOS)
  • the hinge region comprises a hinge region of CD8 alpha, a hinge region of human immunoglobulin (Ig) , or a glycine-serine rich sequence.
  • the CADAR comprises a hinge region of CD8 alpha, CD28, ICOS or IgG4m.
  • the hinge region has a sequence of SEQ ID NO: 22, or a sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%sequence identity thereto.
  • the intracellular domain of the CADAR described herein is responsible for activation of at least one of the normal effector functions of the immune cell in which the CADAR has been placed in.
  • effector function used in the context of an immune cell refers to a specialized function of the cell, for example, the cytolytic activity or helper activity including the secretion of cytokines for a T cell.
  • T-cell receptor TCR
  • secondary cytoplasmic signaling sequences those that initiate antigen-dependent primary activation through the TCR (primary cytoplasmic signaling sequences) and those that act in an antigen-independent manner to provide a secondary or co-stimulatory signal (secondary cytoplasmic signaling sequences) .
  • the intracellular domain of the CADAR can be derived from a molecule which transduces the effector function signal and directs the cell to perform the effector function, or a truncated portion of such molecule as long as it transduces the signal.
  • a protein molecule including, but are not limited to, B7-H3, BAFFR, BLAME (SLAMF8) , CD2, CD3 delta, CD3 epsilon, CD3 gamma, CD3 zeta, CD4, CD5, CD7, CD8alpha, CD8beta, CD11a (CD18, LFA-1, ITGAL, ) , CD11b, CD11c, CD11d, CD19, CD27, CD28, CD29, CD30, CD40, CD49a, CD49d, CD49f, CD69, CD79a, CD79b, CD83, CD84, CD86, CD96 (Tactile) , CD100 (SEMA4D) , CD103, CD127, CD137 (4-1BB
  • the intracellular domain comprises a co-stimulatory domain and a signaling domain, wherein upon binding of the CADAR to the ADA, the co-stimulatory domain provides co-stimulatory intracellular signaling without the need of its original ligand, and the signaling domain provides the primary activation signaling.
  • the co-stimulatory domain and the signaling domain of the CADAR can be linked to each other in a random or specified order.
  • the co-stimulatory domain is derived from an intracellular domain of a co-stimulatory molecule.
  • co-stimulatory molecules examples include B7-H3, BAFFR, BLAME (SLAMF8) , CD2, CD4, CD8 alpha, CD8 beta, CD7, CD11a, CD11b, CD11c, CD11d, CD 18, CD 19, CD27, CD28, CD29, CD30, CD40, CD49a, CD49D, CD49f, CD69, CD83, CD84, CD96 (Tactile) , CD100 (SEMA4D) , CD103, CD 127, CD137 (4-1BB) , CD150 (SLAM, SLAMF1, IPO-3) , CD160 (BY55) , CD162 (SELPLG) , CD226 (DNAM1) , CD229 (Ly9) , CD244 (SLAMF4, 2B4) , CEACAM1, CRTAM, CDS, OX40, PD-l, ICOS, GADS, GITR, HVEM (LIGHTR) , IA4, ICAM-l, IL2R beta,
  • the co-stimulatory domain of the CADAR comprises an intracellular domain of co-stimulatory molecule CD137 (4-1BB) , CD28, OX40 or ICOS.
  • the co-stimulatory domain of the CADAR has a sequence of SEQ ID NO: 23. or a sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%sequence identity thereto.
  • the primary activation of the TCR complex can be regulated by a primary cytoplasmic signaling sequence either in a stimulatory manner or in an inhibitory manner.
  • Primary cytoplasmic signaling sequences that act in a stimulatory manner may contain signaling motifs known as immunoreceptor tyrosine-based activation motifs (ITAMs) .
  • ITAMs immunoreceptor tyrosine-based activation motifs
  • Examples of ITAM containing primary signaling sequences include those derived from CD3 gamma, CD3 delta, CD3 epsilon, CD3 zata, CD5, CD22, CD79a, CD79b, CD66d, FcR gamma, FcR beta, and TCR zeta, .
  • the signaling domain of the CADAR of the disclosure comprises an ITAM that provides stimulatory intracellular signaling upon the CADAR binding to the ADA, without HLA restriction.
  • the signaling domain of the CADAR comprises a signaling domain of CD3 zeta (CD247) .
  • the signaling domain of the CADAR comprises a sequence of SEQ ID NO: 24, or a sequence having at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%sequence identity thereto.
  • the CADAR further comprises a linker.
  • linker as provided herein is a polypeptide connecting various components of the CADAR.
  • the linker is inserted between the VH and VL of the scFv. In some embodiments, the linker is inserted between the transmembrane domain and the intracellular domain. In some embodiments, the linker is between the signaling domain and the co-stimulatory domain of the intracellular domain.
  • the linker comprises a glycine-serine (GS) doublet between 2 and 20 amino acid residues in length.
  • GS doublets include (G4S) 3 : SEQ ID NO: 25.
  • the polynucleotide provided herein comprises a nucleotide sequence encoding a linker.
  • the CADAR provided herein comprises from the N-terminus to the C-terminus: a signal peptide of CD8 alpha, an immunogenic fragment of adalimumab (e.g., a sequence selected from Table 2 or scFv derived from adalimumab) , a hinge region of CD8 alpha, a transmembrane domain of CD8 alpha, an intracellular domain of CD137, and a signaling domain of CD3 zeta.
  • a signal peptide of CD8 alpha e.g., a sequence selected from Table 2 or scFv derived from adalimumab
  • the polynucleotide provided herein encodes a CADAR comprising from the N-terminus to the C-terminus: a signal peptide of CD8 alpha, an immunogenic fragment of adalimumab (e.g., a scFv derived from adalimumab) , a hinge region of CD8 alpha, a transmembrane domain of CD8 alpha, an intracellular domain of CD137, and a signaling domain of CD3 zeta.
  • a CADAR comprising from the N-terminus to the C-terminus: a signal peptide of CD8 alpha, an immunogenic fragment of adalimumab (e.g., a scFv derived from adalimumab) , a hinge region of CD8 alpha, a transmembrane domain of CD8 alpha, an intracellular domain of CD137, and a signaling domain of CD3 zeta.
  • the CADAR demonstrates a high affinity to an ADA against a therapeutic TNF-alpha monoclonal antibody.
  • affinity refers to the strength of non-covalent interaction between an immunoglobulin molecule or fragment thereof and an antigen.
  • the binding affinity can be represented by Kd value, i.e., the dissociation constant, determined by any methods known in the art, including, without limitation, enzyme-linked immunosorbent assays (ELISA) , surface plasmon resonance, or flow cytometry (such as FACS) .
  • the CADAR has a binding affinity to the ADA of less than 50 nM, 25nM, 10 nM, 5 nM, 4 nM, 3 nM, 2 nM, or 1 nM.
  • the present disclosure provides a vector comprising the polynucleotide encoding the CADAR as described herein.
  • the polynucleotides encoding a CAR can be inserted into different types of vectors known in the art, for example, a plasmid, a phagemid, a phage derivative, a viral vector derived from animal virus, a cosmid, transposon, a site directed insertion vector (e.g., CRISPR, Zinc finger nucleases, TALEN) , or a suicide expression vector.
  • the vector is a DNA or RNA.
  • the polynucleotide is operatively linked to at least one regulatory polynucleotide element in the vector for expression of the CADAR.
  • Typical vectors contain various regulatory polynucleotide elements, for example, elements (e.g., transcription and translation terminators, initiation sequences, and promoters) regulating the expression of the inserted polynucleotides, elements (e.g., origin of replication) regulating the replication of the vector in a host cell, and elements (e.g., terminal repeat sequence of a transposon) regulating the integration of the vector into a host genome.
  • elements e.g., transcription and translation terminators, initiation sequences, and promoters
  • elements e.g., origin of replication
  • elements e.g., terminal repeat sequence of a transposon
  • the expression of the CADAR can be achieved by operably linking the polynucleotides encoding a CADAR to a promoter, and incorporating the construct into a vector.
  • constitutive promoters such as a CMV promoter, a SV40 promoter, and a MMTV promoter
  • inducible promoters such as a metallothionine promoter, a glucocorticoid promoter, and a progesterone promoter
  • the vector is an expression vector
  • An expression vector comprises sufficient cis-acting elements for expression; other elements for expression can be supplied by the host cell or in an in vitro expression system.
  • the vector can also comprise a selectable marker gene or a reporter gene or both for identification and selection of the cells to which the vector are introduced.
  • selectable markers include, for example, antibiotic-resistance genes, such as neo and the like.
  • Useful reporters include, for example, luciferase, beta-galactosidase, chloramphenicol acetyl transferase, secreted alkaline phosphatase, or the green fluorescent protein gene.
  • the vector is a viral vector.
  • Viral vectors may be derived from, for example, retroviruses, adenoviruses, adeno-associated viruses (AAV) , herpes viruses, and lentiviruses.
  • Useful viral vectors generally contain an origin of replication functional in at least one organism, a promoter, restriction endonuclease sites, and one or more selectable markers.
  • the vector is a retrovirus vector, such as lentiviral vector.
  • Lentiviral vector is particular useful for long-term, stable integration of the polynucleotide encoding the CADAR into the genome of non-proliferating cells that result in stable expression of the CADAR in the host cell, e.g., host T cell.
  • the vector is mRNA, which can be electroporated into the host cell. As the mRNA would dilute out with cell division, the expression of the mRNA would not be permanent.
  • the vector is a transposon-based expression vector.
  • a transposon is a DNA sequence that can change its position within a genome.
  • the polynucleotide encoding the CADAR is flanked by terminal repeat sequences recognizable by a transposase which mediates the movement of the transposon.
  • a transposase can be co-delivered as a protein, encoded on the same vector as the CADAR, or encoded on a separate vector.
  • Non-limiting examples of transposon systems include Sleeping Beauty, Piggyback, Frog Prince, and Prince Charming.
  • a vector can be introduced into a host cell, e.g., mammalian cell by any method known in the art, for example, by physical, chemical or biological means.
  • Physical methods for introducing a polynucleotide into a host cell include calcium phosphate precipitation, lipofection, particle bombardment, microinjection, electroporation, and the like.
  • Biological methods include the use of viral vectors, and especially retroviral vectors, for inserting genes into mammalian, e.g., human cells.
  • Chemical means include colloidal dispersion systems, such as macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes.
  • the disclosure provides an engineered cell comprising or expressing the CADAR as described here.
  • the engineered cell comprises the polynucleotide encoding the CADAR, or the vector comprising the CADAR polynuleotide.
  • an engineered cell comprises multiple CADAR comprising different immunogenic fragments of a therapeutic anti-TNF-alpha monoclonal antibody.
  • Immune cells useful for the disclosure include T cells, natural killer (NK) cells, invariant NK cells, or NKT cells, and other effector cell.
  • the immune cells are primary cells, expanded cells derived from primary cells, or cells derived from stem cells differentiated in vitro.
  • an engineered cell comprising or expressing a CADAR to have high affinity for ADA-based B cell receptors (BCRs) on B cells, wherein the ADA specifically binds a therapeutic TNF-alpha monoclonal antibody.
  • BCRs ADA-based B cell receptors
  • the engineered cell can induce direct killing of anti-therapeutic TNF-alpha monoclonal antibody B cells or indirect killing of plasma cells expressing ADA against the therapeutic antibody.
  • the engineered cell has low affinity for ADA bound to an Fc receptor.
  • the disclosure provides a method of making an engineered cell expressing the CADAR as described herein.
  • the method comprising one of more steps selected from of obtaining cells from a source, culturing cells, activating cells, expanding cells and engineering cells
  • the disclsoure provides a method of using the engineered cells for cell therapy, wherein the engineered cells are introducing into a subject.
  • the subject is the same subject from who the cells are obtained.
  • the engineered cells can be derived from immune cells isolated from subjects, e.g., human subjects.
  • the immune cells are obtained from a subject of interest, such as a subject suspected of having a particular disease or condition, a subject suspected of having a predisposition to a particular disease or condition, a subject who will undergo, is undergoing, or have undergone treatment for a particular disease or condition, a subject who is a healthy volunteer or healthy donor, or from blood bank.
  • the cells can be autologous or allogeneic to the subject of interest. Allogeneic donor cells may not be human-leukocyte-antigen (HLA) -compatible, and thus allogeneic cells can be treated to reduce immunogenicity.
  • HLA human-leukocyte-antigen
  • Immune cells can be collected from any location in which they reside in the subject including, but not limited to, blood, cord blood, spleen, thymus, lymph nodes, pleural effusion, spleen tissue, and bone marrow.
  • the isolated immune cells may be used directly, or they can be stored for a period of time, such as by freezing.
  • the engineered cells are derived from T cells.
  • T cells can be obtained from blood collected from a subject using any number of techniques known to the skilled artisan, such as apheresis.
  • one or more of the T cell populations is enriched for or depleted of cells that are positive for a specific marker, such as surface markers, or that are negative for a specific marker.
  • markers are those that are absent or expressed at relatively low levels on certain populations of T cells but are present or expressed at relatively higher levels on certain other populations of T cells.
  • CD4+helper and CD8+ cytotoxic T cells are isolated.
  • CD8+ and CD4+ T cells are further enriched for or depleted of naive, central memory, effector memory, and/or central memory stem cells, such as by positive or negative selection based on surface antigens associated with the respective subpopulation.
  • the immune cells are activated and expanded prior to genetic modification. In other embodiments, the immune cells are activated, but not expanded, or are neither activated nor expanded prior to use.
  • the T cells can be activated and expanded by contacting with a surface having attached thereto an agent that stimulates a CD3/TCR complex associated signal and a ligand that stimulates a co-stimulatory molecule on the surface of the T cells.
  • an anti-CD3 antibody and an anti-CD28 antibody can be used.
  • the present disclosure provides a method of boosting response to or alleviating adverse effects associated with the treatment with a therapeutic anti-TNF alpha monoclonal antibody in a subject in need thereof, comprising an effective amount of the engineered cell described herein.
  • the subject suffers a disorder that may benefit from anti-TNF alpha therapy, e.g., a therapy using a therapeutic anti-TNF-alpha monoclonal antibody.
  • disorders that may benefit from an anti-TNF alpha therapy include rheumatoid arthritis (RA) , Juvenile idiopathic arthritis (JIA) , psoriatic arthritis (PsA) , ankylosing spondylitis (AS) , adult Crohn’s disease (CD) , pediatric Crohn’s disease, ulcerative colitis (UC) , plaque psoriasis (Ps) , hidradenitis suppurativa (HS) and uveitis (UV) .
  • RA rheumatoid arthritis
  • JIA Juvenile idiopathic arthritis
  • PsA psoriatic arthritis
  • AS ankylosing spondylitis
  • CD adult Crohn’s disease
  • UC ulcerative colitis
  • the subject fails to respond to the treatment with a therapeutic anti-TNF alpha monoclonal antibody from the very beginning, losses initial achieved response, or respond adversely.
  • Term” response refers to adequate beneficial response of a subject to a treatment.
  • the therapeutic anti-TNF alpha monoclonal antibody induces ADAs in the subject.
  • the engineered cell comprising or expressing a CADAR is derived from T cells isolated from a subject, expanded ex vivo, engineered to comprise a vector for expressing the CADAR, and transfused into the subject.
  • the engineered T cells recognize B cells expressing and presenting ADA-based BCR, wherein the ADA specifically target a therapeutic anti-TNF-alpha monoclonal antibody, and the engineered T cells become activated, resulting in killing of the targeted B cells.
  • the T cells are autologous cell.
  • the treatment method further comprises administering an agent that increases the efficacy of the engineered cells.
  • an agent that increases the efficacy of the engineered cells for example, a growth factor that promotes the growth and activation of the engineered cells of the present disclosure is administered to the subject either concomitantly with the cells or subsequently to the cells.
  • the growth factor can be any suitable growth factor that promotes the growth and activation of the immune cells.
  • Suitable immune cell growth factors include interleukin (IL) -2, IL-7, IL-15, and IL-12, which can be used alone or in various combinations, such as IL-2 and IL-7, IL-2 and IL-15, IL-7 and IL-15, IL-2, IL-7 and IL-15, IL-12 and IL-7, IL-12 and IL-15, or IL-12 and IL2.
  • IL interleukin
  • the treatment method further comprises administering an agent that reduces of ameliorates a side effect associated with the administration of the engineered cells.
  • exemplary side effects include cytokine release syndrome (CRS) , and hemophagocytic lymphohistiocytosis (HLH, also termed macrophage activation syndrome (MAS) ) .
  • the agent administered to treat the side effects can be an agent neutralizing soluble factors such as IFN-gamma, IFN-alpha, IL-2 and IL-6.
  • agents include, without limitation, an inhibitor of TNF-alpha (e.g., entanercept) and an inhibitor of IL-6 (e.g., tocilizumab) .
  • Therapeutically effective amounts of the engineered cells can be administered by a number of routes, including parenteral administration, for example, intravenous, intraperitoneal, intramuscular, intrasternal, or intraarticular injection, or infusion.
  • parenteral administration for example, intravenous, intraperitoneal, intramuscular, intrasternal, or intraarticular injection, or infusion.
  • the engineered cells can be administered in treatment regimens consistent with the immune response to a therapeutic anti-TNF-alpha monoclonal antibody, for example a single or a few doses over one to several days or periodic doses over an extended time.
  • the precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the immune response to a therapeutic anti-TNF-alpha monoclonal antibody, and should be decided according to the judgment of the practitioner and each patient's circumstances.
  • the therapeutically effective amount of engineered cells will be dependent on the subject being treated, the severity and type of the affliction, and the manner of administration.
  • doses that could be used in the treatment of human subjects range from at least 3.8 x 10 4 , at least 3.8x 10 5 , at least 3.8x 10 6 , at least 3.8x 10 7 , at least 3.8x 10 8 , at least 3.8x 10 9 , or at least 3.8x 10 10 cells/m2.
  • the dose used in the treatment of human subjects ranges from about 3.8x 10 9 to about 3.8x 10 10 cells/m 2 .
  • a therapeutically effective amount of the engineered cells can vary from about 5 x 10 6 cells per kg body weight to about 7.5 x10 8 cells per kg body weight, such as about 2x 10 7 cells to about 5x 10 8 cells per kg body weight, or about 5 x 10 7 cells to about 2x 10 8 cells per kg body weight.
  • the exact amount of engineered cells is readily determined by one of skill in the art based on the age, weight, sex, and physiological condition of the subject. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems.
  • the engineered cell comprising a CADAR can be administered before, during, following, or in any combination relative to the treatment with a therapeutic anti-TNF alpha monoclonal antibody.
  • the present disclosure also provides a pharmaceutical composition
  • a pharmaceutical composition comprising the engineered cells and a pharmaceutically acceptable diluent and/or carrier.
  • diluent and/or carrier include buffers such as neutral buffered saline, phosphate buffered saline and the like; carbohydrates such as glucose, mannose, sucrose or dextrans, mannitol; proteins; polypeptides or amino acids such as glycine; antioxidants; chelating agents such as EDTA or glutathione; adjuvants (e.g., aluminum hydroxide) ; and preservatives.
  • Compositions of the present invention are in one aspect formulated for intravenous administration.
  • Example 1 Expression of CADAR in human primary T cells.
  • a transfer plasmid that includes the DNA sequence encoding a CADAR (see FIG. 2 for schematics of the structure) comprising a scFv derived from adalimumab (scFv-ADL) was designed and synthesized (Genewiz, NJ) .
  • the transfer plasmid was then used to generate VSV-G pseudo-typed lentiviral particles using a 4 th generation packaging system.
  • 293T cells were transfected at a confluency of 80%with a mixture of the transfer plasmid, the envelope plasmid, the packaging plasmids and Lipofectamine 30000 (Life Technologies) .
  • Lentivirus containing supernatant was harvested after 49 hours, filtered through a 0.45 micro PES membrane, concentrated at 1500xg for 45 min at at 4°C and stored at -80°C.
  • Human PBMC from healthy donor were activated with CD3/CD28 Dynabeads (Thermo Fisher Scientific) at a 1: 1 cell/bead ratio for 24 hrs.
  • 2E+6 T cells were transduced with the lentivirus particles.
  • T cells were cultured in XF T Cell Expansion Medium (STEMCELL Technologies) supplemented with 50 U/ml IL-2 (Thermo Fisher Scientific) . Media was changed every 2 to 3 days. D5 after stimulation, positive CADAR-T cells were validated by flow cytometry (Beckman cytoflex) .
  • Example 2 In vitro efficacy test of CADAR-T cell.
  • Anti-Adalimumab (ADL) hybridoma cells were generated by immunizing Balb/c mice with purified scFv-ADL protein. B lymphocytes from mouse spleens and myeloma cells were fused. Three rounds of ELISA were used to screen for positive hybridoma clones. One positive (expressing antibodies against ADL) and one negative (not expressing antibodies against ADL) hybridoma cells were cultured in XF T Cell Expansion Medium (STEMCELL Technologies) supplemented with 50 U/ml IL-2 (Thermo Fisher Scientific) and 10%FBS (Gibco) . Media was changed every 1 to 2 days.
  • CFSE CellTrace, Cat C34554
  • 1E+4 hybridoma cell/well were stained with CFSE (2.5 ⁇ M) for 10 minutes at 37°C, washed twice and resuspended in XF T Cell Expansion Medium (STEMCELL Technologies) supplemented with 50 U/ml IL-2 (Thermo Fisher Scientific) and 10%FBS (Gibco) .
  • CADAR-T cells (8 days after initial activation) and activated T cells without CADAR (mock T) were co-incubated with the stained hybridoma cells for 20 hours at various effector: target (E: T) ratios. Subsequently, cells were spun down at 1,000 rpm for 5 mins at room temperature. Fixable Viability Dye eFluor (eBioscience, Cat 65-0863-18) assay was performed in order to label dead cells. CFSE + Fixable Viability Dye eFluor + hybridoma cell percentage was analyzed by flow cytometry (Beckman, cytoflex) . Cytotoxicity of the CARDAR-T cells is calculated based on percent lysis of the hybridoma cells.
  • Killer cytotoxicity CFSE + Fixable Viability Dye eFluor + hybridoma cells with co-incubated scFv-ADL CADAR (%) -CFSE + Fixable Viability Dye eFluor + hybridoma cells with co-incubated mock T (%) .
  • the results of the cytotoxicity assay are shown in Table 5 below. The cytotoxicity of CADAR-T cells increased as E: T ratio increases.
  • INF- ⁇ production in the co-culture of CADAR-T and hybridoma cells was quantified by ELISA (R&D) after co-culture for 20 hrs. The results are shown in Table 6 below.
  • Positive or negative hybridoma cells are injected intravenously into NSG mice after pre-treatment of mice with intravenous immunoglobulin to minimize FcyR-mediated toxicity against BCR-expressing cells.
  • CADAR-T cells or mock T cells
  • Bioluminescence and/or serum ADA are quantified to monitor CADAR-T cell efficacy.
  • CADAR-T cells control the growth of the positive hybridoma cells but not the negative hybridoma cells, whereas the mock T cells do not control the outgrowth of the positive or negative hybridoma cells.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)

Abstract

L'invention concerne un récepteur chimérique d'anticorps anti-médicament (CADAR) spécifique du récepteur des lymphocytes B (BCR) basé sur un anticorps anti-médicament, l'anticorps anti-médicament est induit par un anticorps monoclonal anti-TNF-alpha thérapeutique. L'invention Concerne également des compositions comprenant le CADAR, des polynucléotides codant pour le CADAR, des vecteurs comprenant un polynucléotide codant pour le CADAR, des cellules modifiées comprenant le CADAR, et un procédé utilisant ces derniers.
PCT/CN2021/106404 2020-07-16 2021-07-15 Compositions et procédés permettant de cibler l'anticorps anti-tnf-alpha Ceased WO2022012610A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US18/005,669 US20230287097A1 (en) 2020-07-16 2021-07-15 Compositions and methods to target anti-tnf-alpha antibody
EP21843504.8A EP4182459A4 (fr) 2020-07-16 2021-07-15 Compositions et procédés permettant de cibler l'anticorps anti-tnf-alpha
CN202180002562.8A CN113646433B (zh) 2020-07-16 2021-07-15 靶向抗TNF-α抗体的组合物和方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/102367 2020-07-16
CN2020102367 2020-07-16

Publications (1)

Publication Number Publication Date
WO2022012610A1 true WO2022012610A1 (fr) 2022-01-20

Family

ID=79555073

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/106404 Ceased WO2022012610A1 (fr) 2020-07-16 2021-07-15 Compositions et procédés permettant de cibler l'anticorps anti-tnf-alpha

Country Status (4)

Country Link
US (1) US20230287097A1 (fr)
EP (1) EP4182459A4 (fr)
CN (1) CN113646433B (fr)
WO (1) WO2022012610A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117003870A (zh) * 2023-10-07 2023-11-07 北京丹大生物技术有限公司 一种用于检测阿达木单抗的杂交瘤细胞株组合和抗体组合及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016201300A1 (fr) * 2015-06-12 2016-12-15 Immunomedics, Inc. Traitement de maladies avec des constructions de récepteur d'antigène chimérique (car) et lymphocytes t (car-t) ou cellules nk (car-nk) exprimant des constructions car
CN107267555A (zh) * 2017-05-27 2017-10-20 上海优卡迪生物医药科技有限公司 一种基于octs技术的恶性胶质瘤car‑t治疗载体及其构建方法和应用
CN107827991A (zh) * 2017-11-20 2018-03-23 英普乐孚生物技术(上海)有限公司 靶向cd19的嵌合抗原受体t细胞及其应用
CN107880128A (zh) * 2017-12-21 2018-04-06 常州费洛斯药业科技有限公司 一种抗cd19的全人源抗体或抗体片段及其方法和应用
CN108779160A (zh) * 2016-02-05 2018-11-09 希望之城公司 施用工程化t细胞以治疗中枢神经系统中的癌症

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017096262A1 (fr) * 2015-12-04 2017-06-08 Jomoco, Corp. Compositions et procédés pour atténuer ou prévenir une réponse immunitaire à une molécule thérapeutique immunogène chez des primates non humains
BR112018003984A2 (pt) * 2015-12-09 2018-09-25 Hoffmann La Roche anticorpos
RU2018140056A (ru) * 2016-04-15 2020-05-15 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Композиции и способы с использованием т-клеток с химерным рецептором аллоантигена

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016201300A1 (fr) * 2015-06-12 2016-12-15 Immunomedics, Inc. Traitement de maladies avec des constructions de récepteur d'antigène chimérique (car) et lymphocytes t (car-t) ou cellules nk (car-nk) exprimant des constructions car
CN108779160A (zh) * 2016-02-05 2018-11-09 希望之城公司 施用工程化t细胞以治疗中枢神经系统中的癌症
CN107267555A (zh) * 2017-05-27 2017-10-20 上海优卡迪生物医药科技有限公司 一种基于octs技术的恶性胶质瘤car‑t治疗载体及其构建方法和应用
CN107827991A (zh) * 2017-11-20 2018-03-23 英普乐孚生物技术(上海)有限公司 靶向cd19的嵌合抗原受体t细胞及其应用
CN107880128A (zh) * 2017-12-21 2018-04-06 常州费洛斯药业科技有限公司 一种抗cd19的全人源抗体或抗体片段及其方法和应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP4182459A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117003870A (zh) * 2023-10-07 2023-11-07 北京丹大生物技术有限公司 一种用于检测阿达木单抗的杂交瘤细胞株组合和抗体组合及其应用
CN117003870B (zh) * 2023-10-07 2023-12-12 北京丹大生物技术有限公司 一种用于检测阿达木单抗的杂交瘤细胞株组合和抗体组合及其应用

Also Published As

Publication number Publication date
EP4182459A1 (fr) 2023-05-24
CN113646433A (zh) 2021-11-12
US20230287097A1 (en) 2023-09-14
CN113646433B (zh) 2022-10-11
EP4182459A4 (fr) 2024-08-21

Similar Documents

Publication Publication Date Title
US11866725B2 (en) Optimized lentiviral transfer vectors and uses thereof
US11407804B2 (en) Compositions and methods of chimeric autoantibody receptor T cells
JP7737740B2 (ja) 抗ｇｐｃ３一本鎖抗体を含むｃａｒ
AU2019299439C1 (en) Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
EP3875484A1 (fr) Anticorps ciblant cll1 et son utilisation
CA3032054A1 (fr) Polytherapies de recepteurs d'antigenes chimeriques adn inhibiteurs pd -1
EP3577134A1 (fr) Traitement du cancer à l'aide de protéines chimères du récepteur de lymphocytes t ayant de multiples spécificités
CN116829194A (zh) 用于工程化细胞疗法的靶向细胞因子构建体
US20210261646A1 (en) Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
US20240123068A1 (en) Cd19 binders, car-t constructs comprising the same, and methods of using the same
CA3255500A1 (fr) Récepteur multipartite et complexes de signalisation
WO2023016576A1 (fr) Récepteur d'antigène chimérique ciblant le bcma à base d'anticorps monocaténaire entièrement humain et murin et son utilisation
US20240156962A1 (en) Bcma-targeted car-t cell therapy of multiple myeloma
US20240226154A9 (en) Car-t constructs comprising a novel cd19 binder combined with il18 and methods of using the same
WO2025140265A1 (fr) Combinaison d'un récepteur antigénique chimérique et de dap10 en thérapie cellulaire
CA3229193A1 (fr) Compositions et methodes pour des recepteurs antigeniques chimeriques specifiques des recepteurs de lymphocytes b
WO2022012610A1 (fr) Compositions et procédés permettant de cibler l'anticorps anti-tnf-alpha
CN121152813A (zh) 细胞免疫疗法的组合物和方法
WO2022048621A1 (fr) Compositions et procédés permettant de cibler l'anticorps anti-rh
US20240091263A1 (en) Chimeric antigen receptors targeting albumin and their methods of uses
WO2025016450A1 (fr) Combinaison d'une thérapie par antagoniste ciblant cldn18.2 et gucy2c
US20260027152A1 (en) Antigen Binders Specific For IL-23R And Uses Thereof
WO2026021525A1 (fr) Fractions de liaison à gprc5d et leurs utilisations
WO2024230793A1 (fr) Récepteurs antigéniques chimériques et procédés d'utilisation associés
WO2026011052A1 (fr) Thérapie par cellules car-t contre le cancer du sein triple négatif

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21843504

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021843504

Country of ref document: EP

Effective date: 20230216

WWW Wipo information: withdrawn in national office

Ref document number: 2021843504

Country of ref document: EP